NY-GENERAL-ATLANTIC
9.9.2019 12:02:09 CEST | Business Wire | Press release
Kiwi.com , a leading online travel booking platform powered by cutting-edge technology, today announced a new Board of Directors to guide the Company through its next phase of growth.
Daniel Finnegan, former Chief Financial Officer and Chief Accounting Officer of Booking Holdings (formerly The Priceline Group Inc.), will serve as an independent Board Director. During Mr. Finnegan’s 14-year tenure with Booking Holdings, the company grew to about 22,000 employees and reached a valuation of more than $100 billion.
“I am excited for the opportunity to work with Oliver and the Kiwi team as they build towards ambitious goals that will ultimately provide extraordinary value and experiences to travelers worldwide,” said Daniel Finnegan.
Kiwi.com executives Oliver Dlouhý, Co-founder and CEO, and Juraj Striezenec, CFO, as well as General Atlantic Technology sector team members Tanzeen Syed, Managing Director, and Jessie Cai, Vice President, will also join the Board.
“I am grateful to be surrounded by a group of experts with whom I look forward to closely working as we scale Kiwi.com,” said Oliver Dlouhý. “Our new Board brings a diversity of strategic and operational experience spanning the technology and travel sectors, and Dan’s background as the former CFO of one of the world’s largest travel companies will be invaluable to our business. The creation of this team is an exciting milestone in this next chapter of our growth.”
In June 2019 Kiwi.com announced a strategic investment from General Atlantic , a leading global growth investor, to help scale the business and support management’s vision to create a seamless end-to-end travel experience for customers. General Atlantic has extensive experience in the global online travel industry, with current and past investments including Priceline, Airbnb, Meituan, Flixbus, Uber, Despegar.com, Smiles and Mafengwo.
Tanzeen Syed continued, “We believe the structure and expertise of this Board well-positions Kiwi.com to execute on its vision of creating a comprehensive travel experience for consumers around the globe. The addition of an independent Director of the caliber and experience level of Dan brings further momentum to the business as Kiwi.com enters this next phase of growth. General Atlantic is excited to be working alongside Oliver, the Board and the Kiwi.com team to continue building a next-generation travel technology platform.”
Kiwi.com, a rapidly growing technology company, was founded in 2012 and was recognized as the #1 fastest-growing Czech start-up by Forbes Magazine in 2017 and 2018. Through its proprietary technology and algorithms, Kiwi.com has a unique ability to offer expansive flight options to value-conscious consumers.
The Company pioneered technology that matches passengers to multiple carriers and flights on single itineraries and partners with airlines, online travel agencies, and metasearch engines to sell more than €1 billion in tickets across the globe.
About Kiwi.com
Kiwi.com was founded in 2012 by Oliver Dlouhý and Jozef Képesi. The travel tech company was created for travellers by travellers. Its proprietary algorithm, Virtual Interlining, allows users to combine flights from more than 750 carriers, including many that do not normally cooperate. Kiwi.com also provides its industry-leading Kiwi.com Guarantee, which protects customers from missed connections because of delay, schedule change or cancellation.
Kiwi.com powers more than 100 million flight searches every day and employs over 2,900 people worldwide. It is one of the fastest-growing technology companies in Central Europe. It entered the 2017 Deloitte Technology Fast 500 EMEA list in 7th place, becoming the highest ever ranked Czech company. For the second consecutive year, Kiwi.com was named best Start-up of the Czech Republic by Czech Forbes Magazine in July 2018.
2018 saw the launch of NOMAD, a revolutionary multi-city travel search tool, and Tequila, a B2B platform for partners of all sizes. Also in 2018, Kiwi.com incorporated ground transportation into its search technology.
About General Atlantic
General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom